$BIIB Cashflow Statement | Understand Stock

$BIIB

$252.26 +$1.57 (0.63%) Close

$BIIB Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flow from operating activities:
Net income
Adjustments to reconcile net income to net cash flow from operating activities:
Depreciation and amortization
Impairment of intangible assets
Impairment of ROU asset
Excess and obsolescence charges related to inventory
Amortization of acquired inventory step-up
Acquired in-process research and development
Share-based compensation
Contingent consideration
(Gain)/loss on divestiture of Hillerød, Denmark manufacturing operations
Deferred income taxes
(Gain) loss on strategic investments
(Gain) loss on equity method investment
Gain on sale of equity interest in Samsung Bioepis
Gain on sale of building, net
Gain on sale of priority review voucher, net
Other
Changes in operating assets and liabilities, net of effects of business acquired:
Accounts receivable
Due from anti-CD20 therapeutic programs
Inventory
Accrued expense and other current liabilities
Income tax assets and liabilities
Other changes in operating assets and liabilities, net
Net cash flow provided by (used in) operating activities

Cash flow from investing activities:
Purchases of property, plant and equipment
Proceeds from sales and maturities of marketable securities
Purchases of marketable securities
Contingent consideration paid related to Fumapharm AG acquisition
Acquisition, net of cash acquired
Reata Pharmaceuticals, Inc
Hi-Bio Acquisition
Total acquisition, net of cash acquired
Proceeds from sale of equity interest in Samsung Bioepis
Proceeds from sale of building
Purchase of subsidiaries and affiliates
Proceeds from sale of priority review voucher, net
Acquired in-process research and development
Acquisitions of intangible assets
Proceeds from sales of strategic investments
Other
Net cash flow provided by (used in) investing activities

Cash flow from financing activities:
Purchase of treasury stock
Payments related to issuance of stock for share-based compensation arrangements, net
Proceeds from borrowings
Repayments of borrowings
Repayments of borrowings
Net (distribution) contribution to noncontrolling interest
Contingent consideration payments
Other
Net cash flow provided by (used in) financing activities

Net increase (decrease) in cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents
Cash and cash equivalents, beginning of the year
Cash and cash equivalents, end of the year

Comments